Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Renner, Lorna A ^a   Dicko, Fatoumata ^b   Kouéta, Fla ^c   Malateste, Karen ^d   Gueye, Ramatoulaye D ^e   Aka, Edmond ^f   Eboua, Tanoh K ^g   Azondékon, Alain ^h   Okomo, Uduok ⁱ   Touré, Pety ^j   Ekouévi, Didier ^k   Leroy, Valeriane ^d  

^a UNIVERSITY OF GHANA   (Ghana)

^b HÔPITAL GABRIEL TOURÉ   (Mali)

^c CHU Charles De Gaulle   (Burkina Faso)

^d INSERM   (France)

^e Hopital d'Enfants Albert Royer Dakar   (Senegal)

^f Centre de Prise en Charge de Recherche et de Formation (CePReF)   (Côte d’Ivoire)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^h Service d hépato gastroentérologie de l Hôpital d Instruction des Armées de Cotonou   (Benin)

ⁱ MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^j MTCT Plus Programme   (Côte d’Ivoire)

^k Programme PACCI   (Côte d’Ivoire)

more..

Author keywords

Adverse reactions; Antiretroviral therapy; Children; Cohort studies; HIV infection; West Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEMOGLOBIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BENIN; BODY WEIGHT; BURKINA FASO; CHILD; COTE D'IVOIRE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GAMBIA; GHANA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALI; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENEGAL; SEROLOGY; TREATMENT DURATION; AFRICA; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ADVERSE REACTIONS; ANTIRETROVIRAL THERAPY; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; METHODOLOGY; WEST AFRICA;

AFRICA, WESTERN; ANEMIA; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; ZIDOVUDINE;

ADVERSE REACTIONS; ANTIRETROVIRAL THERAPY; CHILDREN; COHORT STUDIES; HIV INFECTION; WEST AFRICA;

EID: 84891645298     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18024     Document Type: Article

References (37)

1. Laufer MK, van Oosterhout JJ, Perez MA, Kanyanganlika J, Taylor TE, Plowe CV, et al. Observational cohort study of HIV-infected African children. Pediatr Infect Dis J. 2006;25:623-7.
2. Calis JC, van Hensbroek MB, de Haan RJ, Moons P, Brabin BJ, Bates I, et al. HIV-associated anemia in children: a systematic review from a global perspective. AIDS. 2008;22(10):1099-112.
3. Clark TD, Mmiro F, Ndugwa C, Perry RT, Jackson JB, Melikian G, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. Ann Trop Paediatr. 2002;22(1):11-7.
4. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva: WHO; 2006. [cited 2012 March 30] Available from: w]ww.who.int/hiv/pub/guidelines/WHOpaediatric.pdf
5. ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. The Lancet [Internet]. 2013 [cited 2013 July 18]; 381: Available from: http://dx.doi.org/10.1016/S0140- 6736(12)62198-9
6. Okechukwu AA, Gambo D, Okechukwu IO. Prevalence of anaemia in HIV-nfected children at the University of Abuja Teaching Hospital, Gwagwalada. Niger J Med. 2010;19(1):50-7.
7. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d. Ivoire. AIDS. 2004;18:1905-13.
8. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva: WHO; 2011. (WHO/NMH/NHD/MNM/11.1) [cited 2013 March 15] Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf.
9. World Health Organization. World wide prevalence of anaemia 1993-2005. WHO global database on anaemia. [cited 2012 April 4]. Available from: http://whqlibdoc.who.int/publications/2008/9789241596657-eng.pdf
10. Cornet M, Le Hesran JY, Fievet N, Cot M, Personne P, Gounoue R, et al. Prevalence of and risk factors for anemia in young children in Southern Cameroon. Am J Trop Med Hyg. 1998;58(5):606-11.
11. Heckman J, Samie A, Bessong P, Ntsieni M, Hamandi H, Kohler M, et al. Anaemia among clinically well under-fives attending a community health centre in Venda, Limpopo Province. S Afr Med J. 2010;100:7.
12. Greenwell F, Neumann M. Children's anemia levels in West Africa: a good proxy for malaria morbidity? [cited 2012 March 28]. Available from: Paa2006. princeton.edu/download.aspx?submissionid=1268
13. Eley BS, Sive AA, Shuttleworth M, Hussy GD. A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town. South Africa. BMC Infect Dis. 2002;2(1):3.
14. Shet A, Mehta S, Rajagopalan N, Dinakar C, Ramesh E, Samuel NM, et al. Anemia and growth failure among HIV-infected children in India: a retrospective analysis. BMC Pediatrics. 2009;9:37. doi:10.1186/1471-2431-9-37.
15. Owiredu WKBA, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci. 2011;11(1):2-15.
16. Cross Continents Collaboration for Kids: Markers for predicting mortality among untreated HIV-infected children in resource limited settings: a metaanalysis. AIDS 2008;22(1):97-105.
17. Kiragga A, Castelnuovo B, Nakanjako D, Manabe YC. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc. 2010 [cited 2012 March 28]; 13:42. doi:10.1186/1758-2652-13-42.
18. Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, Mhango E, et al. Outcomes and associated risk factors of patients traced after being lost to follow up from anti-retroviral treatment in Lilongwe, Malawi. BMC Infectious Diseases. 2011;11(1):31. doi: 10.1186/1471-2334-11-31.
19. Vreeman RC, Wiehe SE, Ayaya SO, Musick BS, Nyandiko WM. Association of antiretroviral and clinic adherence with orphan status among HIV-infected children in Western Kenya. J Acquir Immune Defic Syndr. 2008;49:163-70.
20. Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G, et al. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis. 2007;196(Suppl 3):S474-81.
21. Fenner L, Brinkhof MWG, Keiser O,Weigel R, Cornell M, Moultrie H, et al. for the International epidemiological Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Early Mortality and Loss to Follow-up in HIV-Infected Children starting Antiretroviral Therapy in Southern Africa. J Acquir Immune Defic Syndr [Internet]. 2010 August 15 [cited 2013 March 17];54(5): 524-32. doi: 10.1097/QAI.0b013e3181e0c4cf.
22. Davies MA, Keiser O, Technau K, Eley B, Rabie H, van Cutsem G, et al. Outcomes of the South Africa National Antiretroviral Treatment Programme for Children: the IeDEA southern Africa Collaboration. S Afr Med J. 2009;99(10): 730-7.
23. Whitescarter J, Miotti P, Bazin B, Blesson S, Arrive E, Marquis B, et al. Low risk of death, but substantial program attrition in pediatric HIV treatment cohorts in sub-Saharan Africa - KIDS-ART-LINC collaboration. J Acquir Immune Defic Syndr. 2008;49(5):523-31.
24. Bolton-Moore C, Mubiana-Mbewe M, Cantrell R, Chintu N, Stringer EM, Chi BH, et al. Clinical Outcomes and CD4 response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888-99.
25. Wamalwa DC, Obimbo E, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC Pediatrics. 2010;10:33. doi:10.1186/1471-2431-10.
26. Volberding PA, Levine AM, Dietrich D, Mildvan D, Mitsuvasu R, Saaq M, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38(10):1454-63.
27. IeDEA Pediatric Working Group. A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa - the International epidemiologic Databases to Evaluate AIDS (IeDEA). Journal of the International AIDS Society [Internet]. 2013;16:17998. [cited 2013 February 28] Available from: http://www.jiasociety.org/index.php/jias/article/view/17998
28. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. HIV Med. 2008;9(5):317-21.
29. Midvan D, Creagh T, Leitz G. Prevalence of anaemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings of the anaemia prevalence study. Curr Med Res Opin. 2007;23(2):343-55.
30. Forna F, Moore D, Mermin J, Brooks JT, Were W, Buchacz K, et al. Haematologic changes associated with Zidovudine following single drug substitution from stavudine in a homebased AIDS care program in rural Uganda. J Int Assoc Physicians AIDS Care (Chic III). 2009;8(2):128-38.
31. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, et al. Prior antiretroviral therapy experience protects against zidovudine related anaemia. HIV Med. 2007;8(7):465-71.
32. Rajesh R, Vidyasagar S, Varma DM, Mohiuddin S, Noorunnisa. Evaluation of incidence of zidovudine induced anaemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy. Int J Risk Saf Med. 2011;23(3):171-80.
33. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S, et al. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res. 2010;132:386-9.
34. Anwikar SR, Bandekar MS, Smrati B, Pazare AP, Tatke PA, Kshirsagar NA. HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. Int J Risk Saf Med. 2011;23(3):163-9.
35. Sullivan PS, Hanson DL, Brooks JT. Impact on haemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients. J Acquir Immune Defic Syndr. 2008;48(2):163-8.
36. Brabin BJ, Premji Z, Verheff F. An analysis of anemia and child mortality. J Nutr. 2001;131(2):636S-48.
37. SSali F, Stohr W, Munderi P, Reid A,Walker AS, Gibb DM, et al. Prevalence, incidence and predictors of severe anaemia with ZDV-containing regimens in African adults with HIV infection within the DART trial. Antiviral Therapy. 2006;11(6):741-9.